Einsatz von Neuen oralen Antikoagulanzien (NOAK) bei onkologischen Patienten
Standard
Einsatz von Neuen oralen Antikoagulanzien (NOAK) bei onkologischen Patienten. / Trappe, Ralf Ulrich; Sinn, Marianne; Riess, Hanno.
in: DEUT MED WOCHENSCHR, Jahrgang 141, Nr. 20, 09.2016, S. 1446-1450.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Einsatz von Neuen oralen Antikoagulanzien (NOAK) bei onkologischen Patienten
AU - Trappe, Ralf Ulrich
AU - Sinn, Marianne
AU - Riess, Hanno
N1 - © Georg Thieme Verlag KG Stuttgart · New York.
PY - 2016/9
Y1 - 2016/9
N2 - There is only limited data for the use of direct oral anticoagulants (DOACs) in tumor patients and no data from prospective randomised trials comparing DOACs to the current standard care: low molecular weight heparine (LMWH). Therefore, DOACs must be used with caution and should be restricted to tumor patients with (1) contraindications for LMWH (e.g. HIT II, phobia of syringe) or (2) to the situations of prolonged anticoagulation after initial therapy with LMWH. Cancer-associated disorders as well as side effects of chemotherapy as nausea and emesis have to be considered as well as potential substance-specific interactions. Data of future clinical trials in prophylaxis and treatment of venous thrombembolism in tumor patients will help to define the role of DOACs in this special patient cohort.
AB - There is only limited data for the use of direct oral anticoagulants (DOACs) in tumor patients and no data from prospective randomised trials comparing DOACs to the current standard care: low molecular weight heparine (LMWH). Therefore, DOACs must be used with caution and should be restricted to tumor patients with (1) contraindications for LMWH (e.g. HIT II, phobia of syringe) or (2) to the situations of prolonged anticoagulation after initial therapy with LMWH. Cancer-associated disorders as well as side effects of chemotherapy as nausea and emesis have to be considered as well as potential substance-specific interactions. Data of future clinical trials in prophylaxis and treatment of venous thrombembolism in tumor patients will help to define the role of DOACs in this special patient cohort.
KW - Administration, Oral
KW - Anticoagulants/administration & dosage
KW - Antineoplastic Agents/administration & dosage
KW - Drug Interactions
KW - Evidence-Based Medicine
KW - Humans
KW - Neoplasms/complications
KW - Risk Factors
KW - Thromboembolism/etiology
KW - Treatment Outcome
U2 - 10.1055/s-0042-112085
DO - 10.1055/s-0042-112085
M3 - SCORING: Review
C2 - 27701688
VL - 141
SP - 1446
EP - 1450
JO - DEUT MED WOCHENSCHR
JF - DEUT MED WOCHENSCHR
SN - 0012-0472
IS - 20
ER -